# VIP + BPC-157 Blend

> This blend pairs vasoactive intestinal peptide (VIP), an endogenous neuropeptide distributed throughout the gut, lungs, and central nervous system, with BPC-157. VIP has drawn research interest for its broad immune-modulating and anti-inflammatory signaling, including in protocols associated with chronic inflammatory response research, while BPC-157 is separately studied for gut-lining and soft-tissue repair. The combination is intended to pair VIP's systemic immune and inflammatory signaling with BPC-157's more localized gastrointestinal and tissue-repair effects. Controlled trials of the combined blend are lacking, and most evidence comes from small studies or preclinical work on each peptide individually. It is not approved for human medical use.

- URL: https://www.lifeconverted.com/peptides/vip-bpc157-blend
- Also known as: VIP/BPC Stack
- Primary category: Healing Blends
- Effectiveness rank: #12 in Healing & Recovery; #9 in Anti-Inflammatory; #4 in Healing Blends
- Evidence level: Moderate evidence
- Route: Subcutaneous (Dosed subcutaneously in most compounded research protocols. VIP is also available separately as a nasal spray in some non-blend formulations, but this particular combination is typically prepared and dosed as an injectable.)
- Dose range: 200-500 mcg
- Dose tiers: low 200 mcg; moderate 350 mcg; high 500 mcg
- Half-life: VIP is reported to be cleared very rapidly, on the order of 1-2 minutes in circulation, while BPC-157 is reported at roughly 4 hours, a substantial mismatch that some protocols address with more frequent VIP-focused dosing.
- Timing: Morning, or split AM/PM
- Cycle: 4 weeks on, 4 weeks off (Many protocols introduce VIP at a low fraction of the eventual target dose given reports of blood-pressure-lowering effects, titrating upward gradually.)
- Storage: Refrigerate after reconstitution (2-8°C) and protect from light. Use within 2-3 weeks is commonly recommended.

## Mechanism of action

VIP binds VPAC1 and VPAC2 receptors distributed widely across immune, gut, and neural tissue, and is studied for its capacity to modulate cytokine release and support mucosal or epithelial integrity in preclinical work. BPC-157 is proposed to support angiogenesis and fibroblast activity at sites of gut or soft-tissue damage. Together, the pairing is described as addressing immune and inflammatory signaling (VIP) alongside structural tissue repair (BPC-157), particularly in gastrointestinal research contexts, though the two have not been studied together directly.

## Reported benefits

- Studied for gut-lining and mucosal support
- Associated with broad anti-inflammatory and immune-modulating activity
- Preclinical neuroprotective research interest
- Supports soft-tissue repair via the BPC-157 component

## Reported side effects

- Flushing or transient drop in blood pressure (associated with VIP)
- Mild nausea
- Dizziness
- Injection site irritation

## Common protocols

- Gut Healing Protocol
- Inflammatory Response Support
- Neuroinflammation Research Stack

## Stacking notes

Because VIP has been associated with transient blood-pressure effects, some research protocols begin with BPC-157 alone before layering in VIP at a small fraction of the intended dose.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer